Regulus(RGLS) - 2024 Q2 - Quarterly Results

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Of icer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO, August 8, 2024 – Regulus Therap ...